Zobrazeno 1 - 10
of 80
pro vyhledávání: '"G. Cerretti"'
Autor:
S. Giunco, M. Padovan, C. Angelini, F. Cavallin, G. Cerretti, M. Morello, M. Caccese, B. Rizzo, D. d’Avella, A.D. Puppa, F. Chioffi, P. De Bonis, V. Zagonel, A. De Rossi, G. Lombardi
Publikováno v:
ESMO Open. 8:101570
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::629def9914503fad3cf0048c987b231e
https://doi.org/10.1016/j.esmoop.2023.101570
https://doi.org/10.1016/j.esmoop.2023.101570
Publikováno v:
Neuro-Oncology. 24:ii90-ii90
Background Glioblastoma (GBM) is the most common and aggressive primary brain cancer. Despite advances in surgical and first-line treatment, all pts relapse. The aim of this study is to evaluate the benefit of metronomic Temozolomide (mTMZ) for recur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eff2a344594be096e7d22aa6d668e2a0
https://doi.org/10.1093/neuonc/noac174.315
https://doi.org/10.1093/neuonc/noac174.315
Publikováno v:
Annals of Oncology. 33:S678
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec241fe6faeed51b56f4ddbb1d85d3df
https://doi.org/10.1016/j.annonc.2022.07.443
https://doi.org/10.1016/j.annonc.2022.07.443
Publikováno v:
Annals of Oncology. 33:S677
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::249f9b13f8e5c5c46b1f6d3b21cf3ce7
https://doi.org/10.1016/j.annonc.2022.07.440
https://doi.org/10.1016/j.annonc.2022.07.440
Publikováno v:
Neuro-Oncology. 24:ii60-ii60
Background Glioblastoma is the most frequent CNS malignant tumor, with high aggressiveness and poor prognosis. Regorafenib has recently demonstrated promising activity in terms of survival in recurrent glioblastoma patients. The impact of thyroid fun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1f48b086208db34ae2b960438eda9a3
https://doi.org/10.1093/neuonc/noac174.209
https://doi.org/10.1093/neuonc/noac174.209
Publikováno v:
Neuro-Oncology. 24:ii95-ii95
Background meningiomas are the most frequent primary brain tumours. The current standard treatment for atypical and anaplastic meningioma can include surgical resection and radiotherapy. Despite the high rate of relapse no systemic treatment is indic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b742fd80a8b9ccc8db4b8fb396e4eea
https://doi.org/10.1093/neuonc/noac174.332
https://doi.org/10.1093/neuonc/noac174.332
Autor:
M. Padovan, M. Maccari, A. Bosio, S. Vizzaccaro, I. Cestonaro, M. Corrà, M. Caccese, G. Cerretti, null M. Fassan, V. Zagonel, G. Lombardi
Publikováno v:
Annals of Oncology. 33:S671
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9911e7b45444cb6c94256fccc28fc02e
https://doi.org/10.1016/j.annonc.2022.07.423
https://doi.org/10.1016/j.annonc.2022.07.423
Autor:
M Padovan, M Maccari, A Bosio, S Vizzaccaro, I Cestonaro, M Corrà, M Caccese, G Cerretti, M Fassan, V Zagonel, G Lombardi
Publikováno v:
Neuro-Oncology. 24:ii29-ii29
Background NGS panels allow the identification of alterations within hundreds of cancer-related genes and can guide a personalized strategy in glioma treatment. Material and Methods From Nov 2019 to Jan 2022 at Veneto Institute of Oncology, Padua, It
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c73c4c5ece1b818b729228fab87d301
https://doi.org/10.1093/neuonc/noac174.095
https://doi.org/10.1093/neuonc/noac174.095
Publikováno v:
Neuro-Oncology. 24:ii90-ii90
Background Angiogenesis is one of the most distinctive hallmarks of glioblastoma (GBM). Although bevacizumab did not show to improve overall survival in phase 3 trials, it was approved by FDA and is often prescribed as off-label therapy in the recurr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f4cc67bdd560334ce6ecf99cf50fdca
https://doi.org/10.1093/neuonc/noac174.314
https://doi.org/10.1093/neuonc/noac174.314
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.